Schedule 13D ownership disclosure
Design Therapeutics Inc
Common Stock · CUSIP: 25056L103
Event date: 2025-11-14
Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.
- Filing-level shares
- Unavailable
- Percent of class
- Unavailable
- Logos Global Management LPReported CIK 0001792126
Shares: 2,500,000.00 · Class: 4.4%
- Logos Global Management GP LLC
Shares: 2,500,000.00 · Class: 4.4%
- Logos Global Master Fund LPReported CIK 0001831371
Shares: 1,500,000.00 · Class: 2.6%
- Logos GP LLC
Shares: 1,500,000.00 · Class: 2.6%
- Arsani WilliamReported CIK 0001848372
Shares: 2,515,000.00 · Class: 4.4%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0000935836-25-000710
- Form type
- SCHEDULE 13D/A
- Filer
- Design Therapeutics, Inc.
- CIK
- CIK 1807120
- Filed
- Nov 18, 2025
- Reporting period
- Nov 14, 2025
- Description
- Schedule 13D beneficial ownership